Seller record · Telehealth service

TideMedix

By Peptide Alliance, Editorial publisherRecorded October 2026 · Standard v1.1 · How checks are performed

Fails 1 of 8 criteria. S5, analytical documentation: The home, FAQ and policy pages publish no certificate of analysis or equivalent lot document.

At a glance

TideMedixTelehealth service

5/8criteria passed

Price: Not yet recorded
Sells: semaglutide, tirzepatide
FDA letters: None on file

Visit TideMedix See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. 2 not verified, counting neither way. Recorded against Standard v1.1.

A telehealth GLP-1 platform advertising an introductory first-month starting price, a private online health assessment and licensed provider review before prescribing medication.

Operating entity The home, contact, privacy and terms pages use TideMedix without identifying a separate legal entity.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	TideMedix's website; TideMedix's FAQ
S2	Prescription gating	PASS	TideMedix's FAQ
S3	Pharmacy identification	NOT VERIFIED	TideMedix's returns refund policy; TideMedix's FAQ
S4	Compounding disclosure	PASS	TideMedix's website
S5	Analytical documentation	FAIL	TideMedix's website; TideMedix's FAQ; TideMedix's returns refund policy
S6	Business address	PASS	TideMedix's contact page; TideMedix's privacy page; TideMedix's returns refund policy
S7	Price disclosure	NOT VERIFIED	TideMedix's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed provider reviews medical history and eligibility before considering treatment, and medication is prescribed only when clinically appropriate.Source: TideMedix's website; TideMedix's FAQ.

S2PASSThe public process begins with a private health assessment, then provider review before a treatment prescription.Source: TideMedix's FAQ.

S3NOT VERIFIEDThe dispensing-pharmacy question did not resolve from the published material. The returns policy names TideMedix/Manifest Pharmacy at a return address, but the public treatment and FAQ pages do not clearly identify Manifest as the pharmacy filling the prescriptions. The check is open.Source: TideMedix's returns refund policy; TideMedix's FAQ.

S4PASSThe home-page disclosure states that compounded drug products are not approved or evaluated by the FDA for safety, effectiveness or quality.Source: TideMedix's website.

S5FAILThe home, FAQ and policy pages publish no certificate of analysis or equivalent lot document.Source: TideMedix's website; TideMedix's FAQ; TideMedix's returns refund policy.

S6PASSThe contact and privacy pages list 5255 Office Park Blvd, Suite 107, Bradenton, FL 34203. The South Carolina address in the return policy is specifically a return destination.Source: TideMedix's contact page; TideMedix's privacy page; TideMedix's returns refund policy.

S7NOT VERIFIEDThe medication-price question did not resolve from the published material. The home page advertises GLP-1 plans from $99 for the first month without connecting the figure to a specific molecule or publishing a continuing price. The check is open.Source: TideMedix's website.

S8PASSNo FDA warning letter names TideMedix, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: semaglutide, tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit TideMedix

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.